Used in targeted cancer therapies, particularly for colorectal, gastric, and pancreatic cancers where CEACAM5 (carcinoembryonic antigen) is overexpressed. This antibody serves as a key component in antibody-drug conjugates (ADCs), delivering cytotoxic agents directly to tumor cells while sparing healthy tissues. It enables precise tumor imaging and detection in diagnostic applications. Due to its high specificity and binding affinity, it supports the development of immunotherapies including radioimmunotherapy and bispecific antibodies. Its role in clinical-stage therapeutics highlights its importance in advancing personalized oncology treatments.